Table 2.

Ongoing clinical trials of daratumumab in multiple myeloma

NCT number	Title	Phase	Number	Recruitment
NCT02116569	A study of daratumumab in Japanese participants with relapsed or refractory multiple myeloma	1	9	Completed
NCT02497378	A study of JNJ-54767414 (daratumumab) in combination with bortezomib and dexamethasone (D-Vd) in Japanese participants with relapsed or refractory multiple myeloma	1	6	Recruiting
NCT02519452	A study of daratumumab with the addition of recombinant human hyaluronidase (rHuPH20) for the treatment of participants with relapsed or refractory multiple myeloma	1	128	Recruiting
NCT02626481	Study of daratumumab in combination with dexamethasone in resistant or refractory multiple myeloma	2	64	Recruiting
NCT02316106	A study to evaluate 3 dose schedules of daratumumab in participants with smoldering multiple myeloma	2	120	Recruiting
NCT02419118	Monoclonal antibodies for treatment of multiple myeloma. Emphasis on the CD38 antibody daratumumab	2/3	50	Recruiting
NCT02076009	A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma	3	571	Active, not recruiting
NCT02136134	Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma	3	497	Active, not recruiting
NCT02541383	A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia)	3	1080	Recruiting
NCT02252172	Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in participants with previously untreated multiple myeloma	3	730	Recruiting
NCT02195479	A study of combination of daratumumab and Velcade (bortezomib) melphalan-prednisone (DVMP) compared to Velcade melphalan-prednisone (VMP) in participants with previously untreated multiple myeloma	3	700	Recruiting